YTH domain family member 3 (YTHDF3) (YTHDF3)

YTH domain family member 3 (YTHDF3) is a cytoplasmic reader protein that specifically recognizes and binds to N6-methyladenosine (m6A)-modified messenger RNA [1]. It functions in coordination with other YTH family members, such as YTHDF1 and YTHDF2, to regulate the translation efficiency and stability of its target transcripts [2]. By facilitating the loading of ribosomes onto m6A-modified mRNAs, YTHDF3 plays a pivotal role in the rapid response of the cellular proteome to various stimuli [3]. In clinical contexts, YTHDF3 is significantly associated with cancer progression; for instance, its upregulation is a key driver of brain metastasis in breast cancer by enhancing the translation of genes involved in blood-brain barrier crossing [4]. Additionally, YTHDF3 has been implicated in the regulation of viral RNA genomes, such as HIV-1 and Zika virus, making it a potential target for antiviral therapies [5]. Although no small-molecule inhibitors are currently in clinical trials, experimental approaches using siRNA and antisense oligonucleotides have demonstrated the potential of modulating YTHDF3 levels to suppress tumor growth and metastasis [6]. The protein's ability to integrate multiple RNA processing signals makes it a complex but promising therapeutic target in oncology and virology [2]. Future drug development may focus on disrupting the YTH domain's interaction with m6A sites to selectively inhibit oncogenic translation [6].

Other names

YTH domain-containing family member 3YTHDF3Protein YTHDF3

Experimental modulation via RNA interference (siRNA) to reduce protein expression or small-molecule inhibition of the YTH domain to block m6A-modified RNA binding [6].